Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
| Revenue (Most Recent Fiscal Year) | $385.69M |
| Net Income (Most Recent Fiscal Year) | $-239.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 107.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -74.44% |
| Net Margin (Trailing 12 Months) | -74.47% |
| Return on Equity (Trailing 12 Months) | -223.51% |
| Return on Assets (Trailing 12 Months) | -39.88% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.22 |
| Inventory Turnover (Trailing 12 Months) | 2.19 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.96 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 48.76M |
| Free Float | 37.61M |
| Market Capitalization | $6.19B |
| Average Volume (Last 20 Days) | 1.10M |
| Beta (Past 60 Months) | 1.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 81.49% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |